Literature DB >> 17712824

Fatty acid amide hydrolase: from characterization to therapeutics.

Geoffray Labar1, Catherine Michaux.   

Abstract

Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme within the amidase-signature family that terminates the action of several endogenous lipid messengers, including oleamide and the endocannabinoid anandamide. The hydrolysis of such messengers leads to molecules devoid of biological activity, and, therefore, modulates a number of neurobehavioral processes in mammals, including pain, sleep, feeding, and locomotor activity. Investigations into the structure and function of FAAH, its biological and therapeutic implications, as well as a description of different families of FAAH inhibitors are the topic of this review.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17712824     DOI: 10.1002/cbdv.200790157

Source DB:  PubMed          Journal:  Chem Biodivers        ISSN: 1612-1872            Impact factor:   2.408


  16 in total

1.  Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid system-related genes in the rat amygdala.

Authors:  Antonia Serrano; Patricia Rivera; Francisco J Pavon; Juan Decara; Juan Suárez; Fernando Rodriguez de Fonseca; Loren H Parsons
Journal:  Alcohol Clin Exp Res       Date:  2011-12-05       Impact factor: 3.455

Review 2.  Biosynthesis, degradation and pharmacological importance of the fatty acid amides.

Authors:  Emma K Farrell; David J Merkler
Journal:  Drug Discov Today       Date:  2008-04-03       Impact factor: 7.851

3.  Inhibition of Fatty Acid Amide Hydrolase (FAAH) by Macamides.

Authors:  M Alasmari; M Bӧhlke; C Kelley; T Maher; A Pino-Figueroa
Journal:  Mol Neurobiol       Date:  2018-06-20       Impact factor: 5.590

4.  Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase.

Authors:  Luigi Capoferri; Marco Mor; Jitnapa Sirirak; Ewa Chudyk; Adrian J Mulholland; Alessio Lodola
Journal:  J Mol Model       Date:  2011-03-02       Impact factor: 1.810

5.  The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119.

Authors:  Virginia M Stone; Shalinee Dhayal; David M Smith; Carol Lenaghan; Katy J Brocklehurst; Noel G Morgan
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

6.  Quantum mechanics/molecular mechanics modeling of fatty acid amide hydrolase reactivation distinguishes substrate from irreversible covalent inhibitors.

Authors:  Alessio Lodola; Luigi Capoferri; Silvia Rivara; Giorgio Tarzia; Daniele Piomelli; Adrian Mulholland; Marco Mor
Journal:  J Med Chem       Date:  2013-03-07       Impact factor: 7.446

7.  Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates.

Authors:  Marco Mor; Alessio Lodola; Silvia Rivara; Federica Vacondio; Andrea Duranti; Andrea Tontini; Silvano Sanchini; Giovanni Piersanti; Jason R Clapper; Alvin R King; Giorgio Tarzia; Daniele Piomelli
Journal:  J Med Chem       Date:  2008-05-29       Impact factor: 7.446

Review 8.  Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies.

Authors:  David R Janero; Subramanian K Vadivel; Alexandros Makriyannis
Journal:  Int Rev Psychiatry       Date:  2009-04

9.  Mutations in Arabidopsis fatty acid amide hydrolase reveal that catalytic activity influences growth but not sensitivity to abscisic acid or pathogens.

Authors:  Sang-Chul Kim; Li Kang; Satish Nagaraj; Elison B Blancaflor; Kirankumar S Mysore; Kent D Chapman
Journal:  J Biol Chem       Date:  2009-09-30       Impact factor: 5.157

10.  Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability.

Authors:  Federica Vacondio; Claudia Silva; Alessio Lodola; Alessandro Fioni; Silvia Rivara; Andrea Duranti; Andrea Tontini; Silvano Sanchini; Jason R Clapper; Daniele Piomelli; Marco Mor; Giorgio Tarzia
Journal:  ChemMedChem       Date:  2009-09       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.